Wragge Lawrence Graham & Co
- Company/Commercial (31)
- Real Estate (21)
- Banking / Finance (19)
- Funds (13)
- Tax (12)
- Employment (10)
- Financial services (9)
- Regulatory and compliance (9)
- PPP/PFI/Commercial projects (8)
- Construction (7)
- Energy (7)
- Information Technology (7)
- Pharma/Biotech (7)
- Competition/EU (6)
- Intellectual Property (6)
- Litigation / Dispute Resolution (6)
- Private Equity (6)
- Pensions (5)
- Public Sector/Local Authority (5)
- Planning (4)
- Business Tax (3)
- Environment (3)
- Healthcare (3)
- Insolvency & restructuring (2)
- Insurance/reinsurance (2)
- Personal tax / Trusts (2)
- Telecoms (2)
- Charities (1)
- Family (1)
- Media/Entertainment/Sport (1)
- Private Client (1)
- Transport (Including aviation and shipping) (1)
- Travel and Tourism (1)
Sort By: Newest first | Oldest first
Wragge Lawrence Graham & Co’s life sciences experts have advised AstraZeneca on its definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine.
Wragge Lawrence Graham & Co’s corporate team has acted for Gigaclear plc on a £30m investment to expand its provision of ultrafast fibre-to-the-premises networks to rural communities.
Wragge Lawrence Graham & Co has advised AstraZeneca on a co-development and commercialisation agreement with Innate Pharma SA, a biopharmaceutical company developing therapeutic antibodies for the treatment of cancer.
The cross-sector energy team at Wragge Lawrence Graham & Co has advised established client Grid Essence on the sale of a portfolio of eight solar PV parks and the subsequent refinancing of the projects.
Wragge Lawrence Graham & Co has advised AIM-traded Staffline on its £34.5m acquisition of A4e Ltd, creating one of the UK’s largest Work Programme providers.
Wragge Lawrence Graham & Co has promoted six new partners, enhancing its capability in corporate, energy, dispute resolution and real estate.
In the past two months Wragge Lawrence Graham & Co’s corporate team has acted for two special purpose acquisition companies on admission to the UK Listing Authority’s Official List and to the London Stock Exchange’s main market.
Wragges has advised long-standing client on a three-year drug discovery collaboration agreement with Orca.
Wragge Lawrence Graham & Co has advised longstanding client Société Générale Capital Partners on the leveraged buyout of specialty chemicals distributor Safic-Alcan from Parquest Capital.
Derwent London plc has exchanged contracts with LaSalle Investment Management, the global real estate investment manager, to acquire a minimum 175-year long leasehold of 20 Farringdon Road.
Wragge Lawrence Graham & Co has advised GlaxoSmithKline (GSK) on the sale of its shareholding interests in biopharmaceutical company Convergence Pharmaceuticals to Biogen Idec.
Wragge Lawrence Graham & Co has advised Birmingham City Council on the sale of the NEC Group to LDC.
Wragge Lawrence Graham & Co has advised real-estate investment trust Empiric Student Property on a £65.6m secondary fundraising.
Ruth Ormston was named ‘Champion of Justice’ at the LLST Awards, while the law firm also won an award recognising its support of the LLST walks.
Wragge Lawrence Graham & Co has advised Formation Capital on its acquisition of NHP for a consideration of £477m.
Chambers UK has placed Wragge Lawrence Graham & Co in 43 categories, 17 of which are in Band 1.
Corporate lawyers from Wragge Lawrence Graham & Co have advised main market client Hyder Consulting on its £300m recommended takeover by ARCADIS.
Wragge Lawrence Graham & Co has advised Euroclear on its agreement with the US’s DTCC to develop a joint collateral processing service.
Wragge Lawrence Graham & Co has strengthened its Paris office with the appointment of a new competition team.
Wragge Lawrence Graham & Co has advised dnata on its acquisition of the entire issued share capital of Stella Travel Services.